DBV Technologies (NASDAQ:DBVT) Announces Quarterly Earnings Results, Misses Expectations By $0.55 EPS

DBV Technologies (NASDAQ:DBVT) posted its quarterly earnings data on Wednesday. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.55), FiscalAI reports. The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.73 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.

DBV Technologies Trading Up 5.1%

DBVT stock traded up $0.52 on Wednesday, hitting $10.65. The company had a trading volume of 225,697 shares, compared to its average volume of 316,799. The stock has a market cap of $669.67 million, a price-to-earnings ratio of -3.03 and a beta of -1.04. The stock’s 50-day simple moving average is $11.79 and its 200 day simple moving average is $17.04. DBV Technologies has a 12-month low of $8.63 and a 12-month high of $26.18.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on DBVT shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Citizens Jmp lifted their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Finally, Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.